You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 22, 2025

CLINICAL TRIALS PROFILE FOR SODIUM TETRADECYL SULFATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Sodium Tetradecyl Sulfate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01347294 ↗ Compare Two Different Sclerosing Agents in the Treatment of Venous Malformations Unknown status Oslo University Hospital Phase 4 2011-08-01 The purpose of this study is to determine the effectiveness of bleomycin, fibrovein and bleomycin and fibrovein in the treatment of venous malformation.
NCT01408732 ↗ Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia Completed American Rhinologic Society Phase 1/Phase 2 2011-02-01 The purpose of this study is to test a novel and tolerable office-based treatment method, sclerotherapy with sodium tetradecyl sulfate, for recurrent epistaxis (nosebleeds) related to Hereditary Hemorrhagic Telangiectasia (HHT) disease.
NCT01408732 ↗ Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia Completed University of Minnesota Phase 1/Phase 2 2011-02-01 The purpose of this study is to test a novel and tolerable office-based treatment method, sclerotherapy with sodium tetradecyl sulfate, for recurrent epistaxis (nosebleeds) related to Hereditary Hemorrhagic Telangiectasia (HHT) disease.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Sodium Tetradecyl Sulfate

Condition Name

Condition Name for Sodium Tetradecyl Sulfate
Intervention Trials
Epidermoid Cyst 1
Venous Ulcer 1
Epistaxis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Sodium Tetradecyl Sulfate
Intervention Trials
Varicose Veins 1
Epistaxis 1
Hemorrhoids 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Sodium Tetradecyl Sulfate

Trials by Country

Trials by Country for Sodium Tetradecyl Sulfate
Location Trials
United States 7
Pakistan 1
Norway 1
Portugal 1
Finland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Sodium Tetradecyl Sulfate
Location Trials
Pennsylvania 1
Washington 1
New Jersey 1
Massachusetts 1
Maryland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Sodium Tetradecyl Sulfate

Clinical Trial Phase

Clinical Trial Phase for Sodium Tetradecyl Sulfate
Clinical Trial Phase Trials
Phase 4 1
Phase 3 1
Phase 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Sodium Tetradecyl Sulfate
Clinical Trial Phase Trials
Recruiting 4
Completed 2
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Sodium Tetradecyl Sulfate

Sponsor Name

Sponsor Name for Sodium Tetradecyl Sulfate
Sponsor Trials
Universidade do Porto 1
Combined Military Hospital, Pakistan 1
Goldman, Butterwick, Fitzpatrick and Groff 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Sodium Tetradecyl Sulfate
Sponsor Trials
Other 11
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sodium Tetradecyl Sulfate: Clinical Trials, Market Analysis, and Projections

Overview of Sodium Tetradecyl Sulfate

Sodium tetradecyl sulfate (STS) is an anionic surfactant widely used in the medical field, particularly in sclerotherapy for the treatment of varicose veins and other vascular anomalies. Here, we will delve into the current state of clinical trials, market analysis, and future projections for this drug.

Clinical Uses and Mechanism of Action

STS is FDA-approved for the treatment of varicose veins but has numerous off-label applications, including the treatment of telangiectasias, hemangioma, pyogenic granuloma, and other vascular malformations. The mechanism of action involves the induction of intima inflammation and thrombus formation upon intravenous injection, leading to the occlusion and eventual obliteration of the injected vein[1][3].

Clinical Trials

Several clinical trials are ongoing or have been completed to assess the efficacy and safety of STS in various applications:

  • Varicose Veins and Vascular Malformations: Clinical trials have consistently shown the efficacy of STS in treating varicose veins and other vascular anomalies. These trials often involve sclerotherapy injections to induce vein occlusion and subsequent fibrous tissue formation[1][3].
  • Hereditary Hemorrhagic Telangiectasia (HHT): A study is currently exploring the impact of 3% STS sclerotherapy in subjects diagnosed with HHT, focusing on intranasal intralesional injections. This trial aims to evaluate the safety and efficacy of STS in managing symptoms associated with HHT[4].

Adverse Effects

While STS is generally effective, it is associated with several adverse effects. Common side effects include pain, erythema, swelling, hyperpigmentation, telangiectatic matting, and ulceration. More serious side effects, such as anaphylaxis, pulmonary embolism, stroke, and myocardial infarction, have also been reported[3].

Market Analysis

The market for STS injections has experienced significant growth and is expected to continue this trend.

Market Size and Segmentation

  • The global STS injection market is segmented based on type (1% and 3% concentrations) and application (adult and geriatric use), as well as geographical regions (North America, Europe, Asia-Pacific, South America, and Middle East and Africa)[2][5].
  • The market has shown rapid growth in recent years, with forecasts indicating continued expansion from 2023 to 2031. This growth is driven by increasing demand for sclerotherapy treatments and the simplicity and cost-effectiveness of STS[2].

Geographical Analysis

  • The market analysis covers various regions, highlighting regional supply, demand, and key players. North America, Europe, and Asia-Pacific are significant markets, with each region showing distinct patterns in terms of product pricing, market penetration, and consumer behavior[2][5].

Key Players and Competition

  • The market report includes profiles of global key players, as well as smaller competitors. It provides detailed information on company profiles, main business information, SWOT analysis, sales, revenue, price, and gross margin, along with market share analysis[5].

Market Projections

Forecast Period

  • The market is expected to grow substantially from 2023 to 2031, driven by robust growth rates and positive market dynamics. The forecast includes predictions for market size in terms of revenue across different segments[2].

Drivers and Restraints

  • Drivers include the increasing prevalence of varicose veins and other vascular anomalies, the simplicity and cost-effectiveness of STS treatments, and advancements in sclerotherapy techniques.
  • Restraints may include the potential for serious adverse effects and the availability of alternative treatments[2].

Economic and Social Impact

The growing demand for STS injections reflects broader trends in healthcare, including an aging population and increased awareness of vascular health. The economic impact is significant, with the market expected to reach substantial revenue figures by the end of the forecast period.

Key Takeaways

  • Clinical Efficacy: STS is effective in treating varicose veins and various other vascular malformations.
  • Ongoing Trials: Clinical trials are exploring new applications, such as the treatment of HHT.
  • Market Growth: The STS injection market is experiencing rapid growth and is projected to continue this trend until 2031.
  • Geographical Variations: Market dynamics vary significantly across different regions.
  • Adverse Effects: While generally safe, STS can cause serious side effects, necessitating careful patient selection and monitoring.

FAQs

What is the primary use of Sodium Tetradecyl Sulfate?

Sodium Tetradecyl Sulfate is primarily used as a sclerosing agent in sclerotherapy to treat varicose veins and other vascular anomalies.

What are the common concentrations of Sodium Tetradecyl Sulfate used in treatments?

The common concentrations used are 1% (10 mg/mL) and 3% (30 mg/mL)[2].

What are the potential adverse effects of Sodium Tetradecyl Sulfate?

Common side effects include pain, erythema, swelling, and hyperpigmentation. Serious side effects can include anaphylaxis, pulmonary embolism, stroke, and myocardial infarction[3].

What is the current market trend for Sodium Tetradecyl Sulfate injections?

The market is experiencing rapid growth and is expected to continue this trend until 2031, driven by increasing demand and positive market dynamics[2].

Are there ongoing clinical trials for new applications of Sodium Tetradecyl Sulfate?

Yes, there are ongoing trials, such as the study exploring the impact of 3% STS sclerotherapy in subjects diagnosed with Hereditary Hemorrhagic Telangiectasia (HHT)[4].

Sources

  1. DrugBank: Sodium tetradecyl sulfate: Uses, Interactions, Mechanism of Action.
  2. Market Research Intellect: Global Sodium Tetradecyl Sulfate Injection Market Size, Scope And Forecast 2023-2031.
  3. PubMed: Sodium Tetradecyl Sulfate: A Review of Clinical Uses.
  4. Mayo Clinic: 3% Sodium Tetradecyl Sulfate Sclerotherapy Injections Impact on Hereditary Hemorrhagic Telangiectasia (HHT).
  5. Market Publishers: 2018 Global Sodium Tetradecyl Sulfate (CAS 1191-50-0) Industry Report - History, Present and Future.
Last updated: 2025-01-07

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.